Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This randomized phase II is studying how well giving sorafenib with or without gemcitabine
works in treating patients with metastatic pancreatic cancer. Sorafenib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood
flow to the tumor. Drugs used in chemotherapy, such as gemcitabine, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving sorafenib together with gemcitabine may kill more tumor cells.